Trial Profile
Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study Comparing EG-1962 to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2020
Price :
$35
*
At a glance
- Drugs Nimodipine (Primary) ; Nimodipine (Primary)
- Indications Cerebral ischaemia; Subarachnoid haemorrhage
- Focus Registrational; Therapeutic Use
- Acronyms NEWTON 2
- Sponsors Edge Therapeutics
- 06 Mar 2020 Interim results (n=210) of planned primary analysis assessing evaluating efficacy and safety were published in the Stroke
- 08 Feb 2019 Results presented at the International Stroke Conference 2019
- 27 Jun 2018 According to the Edge Therapeutics media release, company expects to report the final analysis data from all 283 subjects from this study when the data are available later this year.